Hepatocellular Carcinoma

New England Journal of Medicine, Journal Year: 2019, Volume and Issue: 380(15), P. 1450 - 1462

Published: April 10, 2019

Primary liver cancer is the fourth most common tumor worldwide. Hepatocellular carcinoma occurs mainly in context of cirrhosis, hepatitis B or C virus infection, nonalcoholic steatohepatitis. Underlying disease limits therapeutic efficacy.

Language: Английский

---

Hepatocellular carcinoma

The Lancet, Journal Year: 2022, Volume and Issue: 400(10360), P. 1345 - 1362

Published: Sept. 6, 2022

Language: Английский

---

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2020, Volume and Issue: 18(4), P. 223 - 238

Published: Dec. 21, 2020

Language: Английский

---

Advances in immunotherapy for hepatocellular carcinoma

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2021, Volume and Issue: 18(8), P. 525 - 543

Published: April 13, 2021

Hepatocellular carcinoma (HCC) is a prevalent disease with progression that modulated by the immune system. Systemic therapy used in advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs). Immunotherapy checkpoint has shown strong anti-tumour activity subset patients combination anti-PDL1 antibody atezolizumab VEGF-neutralizing bevacizumab or will soon become standard care as first-line for HCC, whereas anti-PD1 agents nivolumab pembrolizumab are after TKIs several regions. Other strategies such adoptive T-cell transfer, vaccination virotherapy have not yet demonstrated consistent clinical activity. Major unmet challenges HCC immunotherapy discovery validation predictive biomarkers, advancing treatment to earlier stages disease, applying liver dysfunction more effective combinatorial sequential approaches. Combinations other systemic local treatments perceived most promising opportunities some already under evaluation large-scale trials. This Review provides up-to-date information on best use currently available immunotherapies therapeutic development. Immunotherapeutic interventions might be tools hepatocellular carcinoma. carcinoma, mechanisms response resistance,

Language: Английский

---

Epidemiology and surveillance for hepatocellular carcinoma: New trends

Journal of Hepatology, Journal Year: 2020, Volume and Issue: 72(2), P. 250 - 261

Published: Jan. 15, 2020

Language: Английский

---

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

The Lancet Oncology, Journal Year: 2021, Volume and Issue: 23(1), P. 77 - 90

Published: Dec. 13, 2021

Language: Английский

---

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2021, Volume and Issue: 18(5), P. 293 - 313

Published: Jan. 28, 2021

Language: Английский

---

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Liver Cancer, Journal Year: 2020, Volume and Issue: 9(6), P. 682 - 720

Published: Jan. 1, 2020

<b><i>Background:</i></b> Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and second leading cause of tumor-related death, thereby posing a significant threat to life health Chinese people. <b><i>Summary:</i></b> Since publication <i>Guidelines for Diagnosis Treatment Liver Cancer (2017 Edition)</i> 2018, additional high-quality evidence has emerged with relevance diagnosis, staging, treatment cancer outside China that requires guidelines be updated. The new edition <i>(2019 was written by more than 70 experts field China. They reflect real-world situation regarding diagnosing treating recent years. <b><i>Key Messages:</i></b> Most importantly, were endorsed promulgated Bureau Medical Administration National Health Commission People’s Republic December 2019.

Language: Английский

---

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Hepatology International, Journal Year: 2020, Volume and Issue: 14(6), P. 889 - 919

Published: Oct. 1, 2020

Language: Английский

---

Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma

Journal of Hepatology, Journal Year: 2019, Volume and Issue: 70(6), P. 1133 - 1144

Published: March 13, 2019

Language: Английский

---